Purpose: Dose-volume histogram (DVH) measurements have been integrated into commercially available quality assurance systems to provide a metric for evaluating accuracy of delivery in addition to gamma analysis. We hypothesize that tumor control probability and normal tissue complication probability calculations can provide additional insight beyond conventional dose delivery verification methods.
hot or cold spots in the target. 10, 11 Furthermore, studies have shown that gamma-based analysis can be insensitive to detect errors or correlate dose errors in anatomic regions of interest. 12, 13 Results derived from the usual individualized pretreatment QA tools have not been related with clinically relevant dosimetric errors on patient dose delivery. A more robust QA than the gamma index would be needed to quantify the clinical impact of dose measured prior to treatment in comparison to planned dose distribution, in addition to estimating the radiobiological implications of any dose differences.
A new approach for plan verification compares independently measured dose-volume histograms (DVHs) to that computed by a treatment planning system (TPS). There are commercially available solutions that incorporate dose measurements on phantom with the CT images of patient to compute pretreatment DVH. The capabilities of producing DVH of the Delta4DVH Anatomy 3D QA system (Scandidos, Uppsala), and both MapCHECK 2 and the ArcCHECK with 3DVH system (Sun Nuclear, Melbourne) have been evaluated in previous studies. [14] [15] [16] New metrics for IMRT QA verification were explored in a study that utilized the COMPASS system (IBA Dosimetry, Bartlett, Tennessee) to incorporate pretreatment DVH into tumor control probability (TCP) and normal tissue complication probability (NTCP) models. 17 TCP provides additional insight to plan quality as it is associated with the clinically observed tumor control rates. Similar association exists between NTCP and radiation-induced toxicity to organs at risk (OAR). These radiobiological metrics offers accountability for the response of specific tissues to dose and dose per fraction, which is not considered in the gamma index. 18 In previous studies, the complication-free tumor control probability, P + , has demonstrated value in approximating complication rates of patients treated. 19 The aim of this work is to demonstrate the value of incorporating P + as a pretreatment verification metric for IMRT plans.
| MATERIALS AND METHODS

2.A | Patient cohort
Fifty-four previously treated VMAT patient plans were used in this study. Prescribed doses and fraction schedules were dependent on the treatment site; however, no patients in the cohort received stereotactic body radiotherapy or radiosurgery. The patients were treated for 5 different anatomical sites consisting of 10 brain, 10 head-neck, 10 lung, 14 pelvis, and 10 prostate patients. There was a variation in the dose, number of fractions, and modalities incorporated in the treatment plans (Table 1) . No patients with extreme circumstances such as prosthetic implants or unusual physiological conditions were included in the study. All structures analyzed in this study are summarized in Table 1 .
Patient plans were planned in Pinnacle 3 TPS (Philips, Koninklijke, Netherlands). The plans were delivered into the Octavius 4D phantom (PTW, Freiburg, Germany), and resulting measurements were compared to the planned dose using conventional gamma analysis.
Two criteria used to test the data were dose difference/distance-toagreement (DTA) of 3%/3 mm and 2%/2 mm normalized to 90% of max dose. The institutional criteria for all these plans were 90% pass rate for all pixels at 3%/3 mm normalized to 90% of max dose. 2%/ 2 mm criteria results are included to examine if simply tightening gamma criteria is indicative of accuracy of delivery.
Phantom measurements were used with the VeriSoft software ver 7.0 (PTW, Freiburg, Germany) to construct delivered DVH by scaling the measurements onto the patient CT set. The patient's DVHs that were originally computed in Pinnacle 3 are then exported to perform radiobiological calculations (details below). The workflow is outlined in Fig. 1 .
2.B | Systems used
Plans were delivered using the same Novalis Tx LINAC (Varian Medical Systems, Palo Alto, California) to mitigate differences that could occur from plan delivery with different LINACs due to variations in treatment planning beam models or configurations.
Pinnacle 3 TPS was used for calculating patient plans in addition
to creating plans to be delivered to the phantom under the same conditions. A 2.5-mm 3 shows DVH produced with Pinnacle 3 overlaid with VeriSoft's DVH for the patient.
2.C | TCP/NTCP modeling
A radiobiological evaluation was performed between the Pinnacle 3 computed plans and the ones calculated from the phantom measurements. The DVH of organs represented in the plan pairs were used for estimation of radiobiological metrics. The formula that is used to calculate the response of each voxel or bin in a DVH for tumors and normal tissues is based on the Poisson model [23] [24] [25] :
where P(D) is the probability of response of a voxel irradiated by uniform irradiation of dose D, D 50 is the dose that induces response to 50% of the patients, and γ is the maximum normalized dose-response gradient. In Eq. (1), the fractionation correction of dose is handled by using the quantity D 2 Gy , which is the equivalent dose at 2 Gy per fraction. 26 The D 2Gy is calculated by the following expression:
where D x Gy is the total dose when x Gy is the dose per fraction. To estimate normal tissue complications (NTCP) from nonuniform dose distributions, the relative seriality model was used:
The overall probability of injury, P I , for several OARs is expressed by the following equation 24, 25 :
where N organs is the total number of vital OARs, and NTCP j is the response probability of the organ j having the reference volume and been irradiated by a dose D i as given by Eq. (1). Furthermore, Δv i is the fractional subvolumes of the organ being irradiated, M is the total number of voxels or subvolumes in the considered organ, and s is relative seriality parameter of that organ. In tumors, for estimating tumor control probability from nonuniform dose distributions, the following model was used:
The overall probability of benefit, P B , can be quantified by the following expression:
where N tumors is the total number of tumors or targets involved in the clinical case. The effectiveness of different treatment plans were evaluated by the radiobiological concept of complication-free tumor control probability, P + , which represents the probability of achieving tumor control without causing damage to normal tissues. 27,28
The radiobiological analysis was based on the DVH from Pinnacle 3 and phantom measurements using the VeriSoft software. The corresponding TCP, NTCP, P I , and P + values were calculated. The difference in these values was obtained to estimate the expected clinical impact of the differences obtained by the dosimetric analysis.
A detailed presentation of the software that was used for the Table 6 summarizes the resulting values for gamma analysis of all cohorts. Γ 3D is the average 3D gamma score, σ Γ 3D is the uncertainty in gamma 3D scores, μ arith is the arithmetic mean, σ μ arith is the uncertainty of the arithmetic mean, μ med is the mean of the medians, and σ μ med is the uncertainty of the mean of medians. The column labeled 'Range' shows the minimum and maximum value of the gammas in the corresponding cohort.
3.A | Gamma analysis
A histogram of values for all the cohorts is shown in Figs. 3 and   4 to visualize the data for both 3%/3 mm and 2%/2 mm criteria. Patients 5 and 6 in the brain cohort as tabulated in Table A1 in Appendix A had 94.8% and 96.4% gamma pass rates with 3%/3 mm tolerance, respectively. The calculated ΔP + of the two plans was −7.94% and −6.82%, respectively, despite having clinically acceptable gamma pass rates. From Table A1 , we can see that the measured dose predicts a reduction of TCP (PTV coverage) compared to the plan, ultimately resulting in a large negative difference.
3.B | TCP/NTCP results
Large reported differences in P I and P + values between the computed and delivered doses are observed in the head-neck patients as tabulated in Table A2 . It has been shown that dosimetric discrepancy of a few percent can have effects on TCP and NTCP. [36] [37] [38] [39] [40] [41] This is also reflected in the low gamma passing rates of head-neck plans.
This may be attributed to poor spatial resolution of measurement against the computed dose in regions of steep dose falloff often witnessed in highly modulated head-neck plans. Table A4 ).
Similarly, the delivered dose to patient eight in the prostate cohort in 
| CONCLUSION
